This observation is consistent with our previous experience with exogenous TSP-1 treatment [28], and implies that short treatment periods with TSP-1 mimetic peptides are not likely to reduce tumor size in melanoma patients if the peptides are used as single treatment. Here, THBS1 is linked to melanoma.